Given the increasingly systematic nature of the study of chromosome 10q status in integrated histopathological and molecular diagnosis of the WHO 2016 classification, combined with highly recommended study of MGMT methylation status, this signature could easily be incorporated into GBM biological and clinical routine. This evidence concerns the gene MGMT and glioblastoma.